share_log

424B5: Prospectus

424B5: Prospectus

424B5：募资说明书
美股sec公告 ·  05/08 07:48
Moomoo AI 已提取核心信息
Clene Inc. has updated its prospectus supplement on May 8, 2024, to adjust the maximum aggregate gross sales price of its common stock offering to $12,300,000. This amendment is filed with the SEC and modifies the previous prospectus supplement dated November 7, 2023, and the accompanying prospectus dated April 26, 2022. The sales of the common stock will be conducted through Canaccord Genuity LLC, acting as the sales agent, on an 'at the market offering' basis as defined by Rule 415(a)(4). Canaccord Genuity is entitled to a commission of up to 3.0% per share sold and will also receive indemnification against certain liabilities. Clene's common stock and public warrants are traded on the Nasdaq under the symbols 'CLNN' and 'CLNNW,' with the last reported sale prices on...Show More
Clene Inc. has updated its prospectus supplement on May 8, 2024, to adjust the maximum aggregate gross sales price of its common stock offering to $12,300,000. This amendment is filed with the SEC and modifies the previous prospectus supplement dated November 7, 2023, and the accompanying prospectus dated April 26, 2022. The sales of the common stock will be conducted through Canaccord Genuity LLC, acting as the sales agent, on an 'at the market offering' basis as defined by Rule 415(a)(4). Canaccord Genuity is entitled to a commission of up to 3.0% per share sold and will also receive indemnification against certain liabilities. Clene's common stock and public warrants are traded on the Nasdaq under the symbols 'CLNN' and 'CLNNW,' with the last reported sale prices on May 6, 2024, being $0.4236 and $0.0393, respectively. The company's public float was valued at approximately $37.0 million as of the date of the supplement. Clene Inc. has not sold any shares under the General Instruction I.B.6 of Form S-3 in the 12 months preceding the date of the new prospectus supplement. The company warns that investing in its securities carries a high degree of risk.
Clene Inc.已于2024年5月8日更新了其招股说明书补充文件，将其普通股发行的最高总销售价格调整为12,300,000美元。该修正案已向美国证券交易委员会提交，修改了先前于2023年11月7日发布的招股说明书补充文件以及随附的2022年4月26日的招股说明书。普通股的销售将通过作为销售代理的Canaccord Genuity LLC在规则415（a）（4）定义的 “市场发行” 基础上进行。Canaccord Genuity有权获得每股最高3.0％的佣金，还将获得某些负债的赔偿。克伦的普通股和公开认股权证在纳斯达克上市，股票代码为 “CLNN” 和 “CLNNW”，上次公布的销售价格为2...展开全部
Clene Inc.已于2024年5月8日更新了其招股说明书补充文件，将其普通股发行的最高总销售价格调整为12,300,000美元。该修正案已向美国证券交易委员会提交，修改了先前于2023年11月7日发布的招股说明书补充文件以及随附的2022年4月26日的招股说明书。普通股的销售将通过作为销售代理的Canaccord Genuity LLC在规则415（a）（4）定义的 “市场发行” 基础上进行。Canaccord Genuity有权获得每股最高3.0％的佣金，还将获得某些负债的赔偿。克伦的普通股和公开认股权证在纳斯达克上市，股票代码为 “CLNN” 和 “CLNNW”，上次公布的销售价格为2024年5月6日，分别为0.4236美元和0.0393美元。截至补编之日，该公司的公众持股量约为3,700万美元。在新招股说明书补充文件发布之日之前的12个月中，Clene Inc.没有根据S-3表格第I.B.6号一般指示出售任何股票。该公司警告说，投资其证券具有高度的风险。

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息